Morningstar

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative ...

Daiichi Sankyo and AstraZeneca’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease progression or death DATROWAY is the ...
Stockhouse

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, ...
Nasdaq

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small ...
Pharmabiz

Datroway demonstrated statistically significant and clinically meaningful improvement in OS as 1st-line therapy for patients with metastatic TNBC for whom immunotherapy was not ...

Positive high-level results from the TROPION-Breast02 phase III trial showed Datroway (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the ...
Morningstar

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
Nasdaq

AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...
ジャパンタイムズ

Breast cancer patients lived longer on drug Datroway, says maker

AstraZeneca and Daiichi Sankyo’s drug Datroway has helped breast cancer patients with a particularly hard to treat form of the disease live longer. Datroway significantly improved survival and also ...
Yahoo Finance

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC ...

Daiichi Sankyo: Pressing The ADC Case Further, Not Being Felt By The Market

Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
Yahoo Finance

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone ...
Seeking Alpha

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del.--(BUSINESS WIRE)-- ...
The Globe and Mail

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for ...